Methods for the preparation of antibodies directed against dithiocarbamates and the use thereof for detection of nitric oxide in body fluids

• US 5,869,348 A
• Filed: 05/15/1996
• Issued: 02/09/1999
• Est. Priority Date: 05/15/1996
• Status: Expired due to Fees

• Current Assignee: Medinox, Inc.
• Original Assignee: Medinox, Inc.
• Inventors: Lai, Ching-San
• Primary Examiner(s): Duffy, Patricia
• Assistant Examiner(s): BAKALYAR, HEATHER
• Application Number:
  US08/644,961
• Time in Patent Office: 1,000 Days
• Field of Search: 514/548, 514/2, 514/22, 514/885, 424/178.1, 424/179.1, 424/181.1, 424/193.1, 424/194.1, 424/600, 436/547
• US Class Current: 436/543
• CPC Class Codes: C07K 16/44 against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA, amino acids
• CPC Class Codes: G01N 33/54353 with ligand attached to the carrier via a chemical coupling agent coatings G01N33/54393
• CPC Class Codes: G01N 33/84 involving inorganic compounds or pH
• CPC Class Codes: Y10S 436/822 Identified hapten

Abstract

In accordance with the present invention, ELISA methods for the measurement of NO levels in mammalian body fluids utilizing monoclonal antibodies directed against dithiocarbamates and related iron complexes are described. It has been found that conjugation of dithiocarbamates to a macromolecule produces immunogenic dithiocarbamate-macromolecule derivatives. Such derivatives can be used for the production (e.g., in rodents) of monoclonal antibodies directed against different forms of dithiocarbamates (e.g., free dithiocarbamates, as well as complexes thereof with iron and, optionally, nitric oxide). In contrast, non-derivatized dithiocarbamates alone are not immunogenic. The simple, easy and non-invasive ELISA methods for measurement of NO levels in body fluids will find a variety of uses, e.g., for diagnosis and monitoring of NO overproduction that has been associated with many inflammatory and infectious diseases.

Claims

1. A method for rendering a dithiocarbamate immunogenic, said method comprising contacting said dithiocarbamate with a macromolecule in the presence of a crosslinking agent under crosslinking conditions wherein said dithiocarbamate and said macromolecule are covalently attached via said crosslinking agent, rendering said dithiocarbamate immunogenic.

2. A method according to claim 1 wherein said dithiocarbamate is selected from compounds having the structure:

space="preserve" listing-type="equation">(R).sub.2 N--C(S)--SH,

wherein each R is independently selected from a C₁ to C₁₈ alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, aroyl, substituted aroyl, acyl, or substituted acyl, or the two R groups can form a 5-, 6- or 7-membered ring including the N and the two R groups.

3. A method according to claim 1 wherein said macromolecule is a polypeptide, a polysaccharide, or a polynucleic acid.

4. A method according to claim 3 wherein said polypeptide is a synthetic, naturally occurring or modified naturally occurring protein.

5. A method according to claim 4 wherein said protein is selected from serum albumin, hemocyanin, ovalbumin or purified protein derivative.

6. A method according to claim 1 wherein said dithiocarbamate is covalently attached to said macromolecule by said crosslinking agent via any functionality on said macromolecule.

7. A method according to claim 6 wherein said functionality on said macromolecule is an amino, hydroxy, sulfhydryl, or carboxyl group.

8. A method according to claim 1 wherein said crosslinking agent is a photoreactive crosslinker or a bifunctional crosslinker.

9. A method according to claim 8 wherein said photoreactive crosslinker is an azido compound or a diazo compound.

10. A method according to claim 9 wherein said photoreactive crosslinker is selected from sulfosuccinimidyl (4-azidosalicylamido)hexanoate, azidobenzoyl hydrazide, N-5-azido-2-nitrobenzoyloxysuccinimide, N-4-(p-azidosalicylamido)butyl-3'"'"'(2'"'"'-pyridyldithio)propionamide, p-azidophenylglyoxal monohydrate, 4-(p-azidosalicylamido) 4-(iodoacetamido)butane, bis (β

-4-azidosalicylamido)ethyl!disufide, N-hydroxysuccinimidyl 4-azidobenzoate, N-hydroxysulfosuccinimidyl 4-azidobenzoate, N-hydroxysuccinimidyl-4-azidosalicylic acid, N-hydroxysulfosuccinimidyl-4-azidosalicylic acid, p-nitrophenyl-2-diazo-3,3,3-trifluoropropionate, 2-diazo-3,3,3-trifluorpropionyl chloride, N-succinimidyl-(4-azidophenyl)-1,3'"'"'-dithiopropionate, sulfosuccinimidyl(4-azidophenyldithio)propionate, sulfosuccinimidyl-2-(7-azido-4-methylcoumarin-3-acetamide)ethyl-1,3'"'"'-dithiopropionate, sulfosuccinimidyl-7-azido-4-methylcoumarin-3-acetate, or sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl-1,3'"'"'-dithiopropionate.

11. A method according to claim 8 wherein said bifunctional crosslinker is a homobifunctional crosslinker or a heterobifunctional crosslinker.

12. A method according to claim 11 wherein said homobifunctional crosslinker is selected from dimethyl adipimidate, dimethyl suberimidate, dimethyl pimilimidate, disuccinimidyl glutarate, disuccinimidyl suberate, bis(sulfosuccinimidyl) suberate, bis(diazo-benzidine), ethylene glycobis(succinimidylsuccinate), disuccinimidyl tartrate, disulfosuccinimidyl tartrate, bismaleidohexane, glutaraldehyde, dithiobis(succinimidyl propionate), dithiobis(sulfosuccinimidyl propionate), 1,4-di 3'"'"',2'"'"'-pyridyldithio(propionamido) butane!, N,N'"'"'-dicyclohexylcarbodiimide, bis 2-(succinimidyloxycarbonyloxy)ethyl!sulfone or dimethyl 3,3'"'"'-dithiobispropion-imidate.

13. A method according to claim 11 wherein said heterobifunctional crosslinker is selected from succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, m-maleimidobenzoyl-N-hydroxysuccinimide ester, succinimidyl-4-(p-maleimidophenyl)butyrate,N-(γ

-maleimidobutyryloxy)succinimide ester, N-succinimidyl(4-iodoacetyl) aminobenzoate, 4-succinimidyl oxycarbonyl-α

-(2-pyridyldithio)toluene, sulfosuccinimidyl-6- α

-methyl-α

-(2-pyridyldithio) toluamido!hexanoate, N-succinimidyl-3-(2-pyridyldithio) propionate, 3-(2-pyridyldithio) propionyl hydrazide, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, 3-(p-azidosalicylamido) butylamine, 1,5-difluoro-2,4-dinitrobenzene or N-hydroxysuccinimidyl 2,3-dibromo-propionate.

15. The product produced by the method of claim 1.

14. A method for preparing an immunogenic dithiocarbamate from a non-immunogenic dithiocarbamate, said method comprising contacting said non-immunogenic dithiocarbamate with a macromolecule in the presence of a crosslinking agent under crosslinking conditions wherein said dithiocarbamate and said macromolecule are covalently attached via said crosslinking agent, rendering said dithiocarbamate immunogenic.

16. An immunogenic dithiocarbamate comprising at least one dithiocarbamate covalently attached via a crosslinking agent to a macromolecule, wherein said dithiocarbamate has the structure

View Dependent Claims (17, 18)

17. An immunogenic dithiocarbamate according to claim 16 wherein said immunogenic dithiocarbamate is further complexed with iron.

18. An immunogenic dithiocarbamate according to claim 17 wherein said immunogenic dithiocarbamate is further complexed with nitric oxide.